Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer-Reference-Cited by-同舟云学术

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Published:2016-02-25 Issue:8 Volume:374 Page:738-748
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Chan John K.,Brady Mark F.,Penson Richard T.,Huang Helen,Birrer Michael J.,Walker Joan L.,DiSilvestro Paul A.,Rubin Stephen C.,Martin Lainie P.,Davidson Susan A.,Huh Warner K.,O’Malley David M.,Boente Matthew P.,Michael Helen,Monk Bradley J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1505067

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant Pleural Effusion: A Multidisciplinary Approach;Open Respiratory Archives;2024-10

2. A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population;International Journal of Gynecologic Cancer;2024-09-03

3. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

4. Hyperthermic intraperitoneal chemotherapy (HIPEC) vs. postoperative intraperitoneal (IP) chemotherapy – Impact on health-related quality of life in primary ovarian cancer patients after cytoreductive surgery;Surgical Oncology Insight;2024-09

5. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial;Med;2024-08